Tenaya Therapeutics, Inc. (TNYA) — Financial statements
Income statement, balance sheet, and cash flow for Tenaya Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 8↓0.4% | 8↓2.5% | 9↓0.3% | 9↑116.5% | 4 | |
| Gross Profit | -8↑0.4% | -8↑2.5% | -9↑0.3% | -9↓116.5% | -4 | |
| Operating Expenses | ||||||
| R&D Expenses | 69↓20.9% | 87↓11.5% | 98↑3.7% | 95↑73.8% | 54 | |
| General & Administrative Expenses | 25 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 25↑19.2% | 21↓15.2% | 24↑9.4% | 22↑55.5% | 14 | |
| Other Expenses | -8 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 85↓21.0% | 107↓12.3% | 123↑4.8% | 117↑70.0% | 69 | |
| Total Costs & Expenses | 93↓19.5% | 116↓11.6% | 131↑4.4% | 126↑72.5% | 73 | |
| Operating Results | ||||||
| Operating Income | -93↑19.5% | -116↑11.6% | -131↓4.4% | -126↓72.5% | -73 | |
| Depreciation & Amortization | 8↓0.4% | 8↓2.5% | 9↓0.3% | 9↑116.5% | 4 | |
| EBITDA | -85↑17.3% | -103↑11.0% | -115↓0.4% | -115↓67.3% | -69 | |
| EBIT | -93↑16.0% | -111↑10.4% | -124↓0.3% | -124↓70.1% | -73 | |
| Interest & Other Income | ||||||
| Net Interest Income | 3↓43.4% | 5↓32.9% | 7↑261.1% | 2↑1709.3% | 0.11 | |
| Interest Income | 3↓43.4% | 5↓32.9% | 7↑261.1% | 2↑1709.3% | 0.11 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -5↑32.2% | -7↓263.4% | -2↓2201.2% | -0.09 | |
| Other Income / Expenses | 3↓43.3% | 5↓32.2% | 7↑263.4% | 2↑2201.2% | 0.09 | |
| Income Before Tax | -91↑18.5% | -111↑10.4% | -124↓0.3% | -124↓70.1% | -73 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -91↑18.5% | -111↑10.4% | -124↓0.3% | -124↓70.1% | -73 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -91↑18.5% | -111↑10.4% | -124↓0.3% | -124↓70.1% | -73 | |
| Bottom-Line Net Income | -91↑18.5% | -111↑10.4% | -124↓0.3% | -124↓70.1% | -73 | |
| EPS (Basic) | -0.59↑55.0% | -1.31↑22.0% | -1.68↑39.1% | -2.76↓63.3% | -1.69 | |
| EPS (Diluted) | -0.59↑55.0% | -1.31↑22.0% | -1.68↑39.1% | -2.76↓63.3% | -1.69 | |
| Weighted Average Shares | 153↑80.3% | 85↑15.0% | 74↑64.6% | 45↑8.6% | 41 | |
| Weighted Average Diluted Shares | 153↑80.3% | 85↑15.0% | 74↑64.6% | 45↑8.6% | 41 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.